Biotech Values

[DewDiligence]

Linear pharmacokinetics is necessary but not sufficient for ruling out a drug-drug interaction. This is especially true when one of the drugs in the combination is a compound like IDX184 that undergoes multiple transformations to be converted into the active (triphosphate) metabolite.

We discussed this topic in detail a couple months back. McBio raised the subject if you recall.

I recall the thread well; it does not appear to be directly related to the SAE’s seen in the DDI study.

I’m not entirely sure what you’re driving at, so perhaps you should spell it out. Why do you think the DDI study showed three SAE’s when the prior separate studies of IDX184 and IDX320 in animals and humans did not?